In the US, there are 170,000 people who have Th2-low asthma Annual cost of current standard of care branded agent ~$25,000 year Therefore, the total U.S. market opportunity for LGM2605 in Th2-low asthma is ~$4.25 Billion per year In the US, there are 160,000 Pulmonary Fibrosis patients Annual cost of current standard of care branded agent ~$100,000 year Therefore, the total U.S. market opportunity for LGM2605 is ~$16 Billion per year
